Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML
Jacqueline Cook, Loren L. Lott, Jenna Perry, Ashley M. Eckel, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen
Abstract
ABSTRACT: Molecular measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.
Topics & Concepts
Core binding factorMyeloid leukemiaMinimal residual diseaseFlow cytometryBiologyImmunologyCancer researchMast cellMolecular biologyLeukemiaGeneticsGeneTranscription factorMast cells and histaminePlatelet Disorders and TreatmentsComplement system in diseases